Steven R. Pollock
Profile
Steven R.
Pollock held several positions in the pharmaceutical industry, including Director at Flex Biomedical, Vice President of Research & Development at APP Pharmaceuticals and Promentis Pharmaceuticals, and Vice President of Regulatory & Medical Affairs at Schwarz Pharma and Actient Pharmaceuticals.
He received an undergraduate degree from the University of Wisconsin and an MBA from Western Michigan University.
Former positions of Steven R. Pollock
| Companies | Position | End |
|---|---|---|
APP Pharmaceuticals, Inc.
 APP Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology APP Pharmaceuticals, Inc. develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. It offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. The company is headquartered in Los Angeles, CA. | General Counsel | - |
Schwarz Pharma, Inc.
 Schwarz Pharma, Inc. Pharmaceuticals: MajorHealth Technology SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI. | Chief Tech/Sci/R&D Officer | - |
Promentis Pharmaceuticals, Inc.
 Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Chief Tech/Sci/R&D Officer | - |
Actient Pharmaceuticals LLC
 Actient Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Actient Pharmaceuticals LLC develops and markets pharmaceutical therapeutic products. The company was founded in March 2009 and is headquartered in Malvern, VA. | Chief Tech/Sci/R&D Officer | - |
Flex Biomedical, Inc.
 Flex Biomedical, Inc. Medical SpecialtiesHealth Technology Flex Biomedical, Inc. develops novel treatments and diagnostics for orthopedic diseases. Its products are synthetic polymers which are designed to treat osteoarthritis, an incurable joint disease. The company was founded by Sal Braico, Hideki Suzuki, Mark W. Grinstaff, Michel Wathier and Brian Snyder in 2007 and is headquartered in Madison, WI. | Director/Board Member | - |
Training of Steven R. Pollock
| University of Wisconsin | Undergraduate Degree |
| Western Michigan University | Masters Business Admin |
Experiences
Positions held
Linked companies
| Private companies | 5 |
|---|---|
Flex Biomedical, Inc.
Flex Biomedical, Inc. Medical SpecialtiesHealth Technology Flex Biomedical, Inc. develops novel treatments and diagnostics for orthopedic diseases. Its products are synthetic polymers which are designed to treat osteoarthritis, an incurable joint disease. The company was founded by Sal Braico, Hideki Suzuki, Mark W. Grinstaff, Michel Wathier and Brian Snyder in 2007 and is headquartered in Madison, WI. | Health Technology |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Health Technology |
Actient Pharmaceuticals LLC
Actient Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Actient Pharmaceuticals LLC develops and markets pharmaceutical therapeutic products. The company was founded in March 2009 and is headquartered in Malvern, VA. | Health Technology |
Schwarz Pharma, Inc.
Schwarz Pharma, Inc. Pharmaceuticals: MajorHealth Technology SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI. | Health Technology |
APP Pharmaceuticals, Inc.
APP Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology APP Pharmaceuticals, Inc. develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. It offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. The company is headquartered in Los Angeles, CA. | Health Technology |
- Stock Market
- Insiders
- Steven R. Pollock
